or Try an Advanced Search...

    Technical Analysis for EDIT - Editas Medicine, Inc.

    Grade Last Price % Change Price Change
    F 5.63 -3.43% -0.20
    EDIT closed down 3.43 percent on Friday, May 24, 2024, on 68 percent of normal volume.
    9 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EDIT trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Inside Day Range Contraction -3.43%
    Crossed Above 20 DMA Bullish -6.48%
    Upper Bollinger Band Touch Strength -6.48%
    Fell Below 20 DMA Bearish 2.18%
    Doji - Bullish? Reversal 2.18%
    Down 3 Days in a Row Weakness 2.18%
    Down 4 Days in a Row Weakness 2.18%
    20 DMA Support Bullish 1.99%
    NR7 Range Contraction 1.99%
    Older End-of-Day Signals for EDIT ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support 4 days ago
    Fell Below 20 DMA 4 days ago
    Down 3% 4 days ago
    Fell Below Previous Day's Low 4 days ago
    Possible Inside Day 4 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    EDIT Chart by TradingView
    Basic chart:

    Profile

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Genetics Enzymes Genetic Engineering Genome DNA CRISPR Genome Editing Cas9

    Is EDIT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 22 EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
    May 16 Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
    May 15 Editas Medicine: Promising Milestone Achieved But Be Patient
    May 14 Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
    May 14 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
    May 12 Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
    May 10 Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
    May 9 Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
    May 9 1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
    May 9 Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
    See more EDIT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.9
    52 Week Low 4.91
    Average Volume 1,920,530
    200-Day Moving Average 8.00
    50-Day Moving Average 6.23
    20-Day Moving Average 5.60
    10-Day Moving Average 5.74
    Average True Range 0.43
    RSI (14) 46.52
    ADX 17.95
    +DI 26.44
    -DI 19.50
    Chandelier Exit (Long, 3 ATRs) 5.40
    Chandelier Exit (Short, 3 ATRs) 6.20
    Upper Bollinger Bands 6.08
    Lower Bollinger Band 5.12
    Percent B (%b) 0.53
    BandWidth 17.08
    MACD Line -0.11
    MACD Signal Line -0.19
    MACD Histogram 0.081
    Fundamentals Value
    Market Cap 459.82 Million
    Num Shares 81.7 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -2.09
    Price-to-Sales 25.99
    Price-to-Book 1.69
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.19
    Resistance 3 (R3) 6.23 6.10 6.09
    Resistance 2 (R2) 6.10 5.96 6.07 6.06
    Resistance 1 (R1) 5.86 5.87 5.80 5.82 6.03
    Pivot Point 5.73 5.73 5.69 5.70 5.73
    Support 1 (S1) 5.49 5.58 5.42 5.44 5.23
    Support 2 (S2) 5.36 5.50 5.33 5.20
    Support 3 (S3) 5.12 5.36 5.17
    Support 4 (S4) 5.07